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The procedure of associating liver partition and portal vein ligation (ALPPS) was 
considered as a potential solution for patients with multifocal liver cancer to 
allow them to undergo extended resection safely. It was then subsequently 
designed as an alternative to either the need for pre-operative portal vein 
ligation or embolization, or alternatively to a two stage hepatic resection, which 
typically involved a significant delay of 4-6 weeks between the first and second 
stages. By clearing tumour from the left lateral section and ligating the branches 
of the portal vein to the intended resected liver combined with transecting the 
parenchyma, ALPPS was thought to result in accelerated liver regeneration of 
the future liver remnant while leaving a partially functioning hemiliver which 
provided sufficient metabolic contribution to prevent liver failure. This allowed a 
much shorter interval between first and second stages of typically 7 days to two 
weeks.  
 
The ALPPS procedure emerged onto the surgical landscape in 2010 following an 
oral presentation of three such treated patients from Germany in a national 
meeting in Berlin and shortly after at the European and African HPB association 
meeting in Cape Town, South Africa in 2011.  A formal paper was published in 
20121. By the time of the next E-AHPBA meeting in Belgrade in 2013 this 
emergence of ALPPS had become more like a crash landing. The procedure had 
been widely adopted by enthusiasts and applied to a large number of clinical 
situations with numerous variations. Some of the presentations of series of 
patients undergoing ALPPS at that meeting described perioperative mortalities 
of up to 20%. Furthermore, case series were presented that included patients 
that left audience scratching their heads over why a conventional one stage 
resection was not performed without exposing the patient to the risk of an 
unnecessary two stage procedure. Since then there have been some very 
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welcome attempts to rationalize ALPPS including the creation of an international 
registry2 and the provision of advice regarding patient selection and exclusion3. 
The way that ALPPS was introduced by the surgical community was unfortunate 
and the indications and patient selection today are much more conservative and 
considered than they were in 2013.  
 
Given the concerns held by many over the way that ALPPS was introduced, with 
little apparent thought to trial or evaluation, it was even more concerning when 
numerous modifications of the procedure started to be described. This may be a 
valid style of experiential learning but coupled with high mortalities and 
morbidities it led to criticisms of surgical bluster, experimentation and risk 
taking. Unfortunately this further endorsed the view that many physicians hold 
of surgeons as lacking the ability to conduct or follow principles of evidence 
based medicine or research in the development of their practice. 
 
The most common indication for ALPPS is multifocal colorectal hepatic 
metastases (CRM). It is worth considering how the outlook has changed for 
patients with CRM over the last two decades. The most significant change in the 
landscape of colorectal cancer has in my opinion been the development of truly 
effective chemotherapy strategies. The introduction of oxaliplatin and irinotecan 
based regimens along with biologics such at cetuximab and bevacizumab led to 
patients having much more consistent tumour responses than was ever seen 
with 5 Fluorouracil based regimens of twenty years ago. This in turn has lead to 
more patients being able to reach a position where they can have liver surgery 
but also has allowed down-sizing of tumours to allow parenchymal sparing 
resections. An additional effect is that the urgency to manage colorectal hepatic 
metastases has been reduced and the overall timeline for management of 
patients has been extended. It is not uncommon now for patients to have several 
separate interventions of surgery or radiofrequency ablation interspersed with 
periods of first, second and third line chemotherapy over many years. 
Importantly all of this is done safely with low operative mortality and low 
mortality from chemotherapy associated complications. Most major units have 
operative mortality rates of 1-2% for patients undergoing surgery for colorectal 
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hepatic metastases. Even reoperation for colorectal liver metastases is not now 
associated with a high mortality and of course there are many second line 
chemotherapies and biologicals which can support surgical and ablative 
strategies. It is in this context that ALPPS should be viewed and this is one of the 
reasons that the high mortality rates presented in 2013 were found to be so 
shocking and unacceptable to many individuals.  
 
In the early years of ALPPS it was clear that some patients were undergoing the 
procedure who did not need it. ALPPS has been performed for patients with an 
adequate future liver remnant for example undergoing right hepatectomy and 
leaving approximately 40% of liver. Similarly the procedure has been applied in 
the patient who could have undergone a more limited procedure such as 
mesohepatectomy or central liver resection to deal with right lobe tumours. In 
my opinion, it is not appropriate to consider ALPPS in these situations until 
ALPPS has an operative mortality approaching the rates for these procedures. 
The Italian registry has highlighted the high mortality of patients who have 
undergone ALPPS for cholangiocarcinoma and has suggested that a moratorium 
should be placed on ALPPS for this indication3. This view is endorsed by ALPPS 
International registry data which have shown a 48% mortality for patients with 
hilar cholangiocarcinoma undergoing ALPPS in expert centres4. 
 
Looking at the causes of death of patients who die after ALPPS procedures, there 
is a common theme of struggling liver function and sepsis. There are some 
patients who fail to show adequate regeneration and yet still proceeded to the 
second stage with subsequent development of fatal liver failure. There are other 
patients who have followed a different pattern. One of the problems with the two 
stage procedure is that the after the first stage perihepatic collections and bile 
leaks are common and reoperation in the second can stir up a septic response. It 
is well known that the combination of a small liver volume and sepsis can be a 
fatal combination5 and in some ways the process of ALPPS creates a perfect 
storm for this complication. Today analysis of experiences and outcomes of 
patients undergoing ALPPS6 has allowed the development of a ‘futility’ score 
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which is useful in determining which patients should proceed to second stage 
and those where discretion should be exercised7.  
 
The ALPPS procedure was thought to supercharge liver regeneration but is this 
really the case? Evidence from comparative studies of kinetic growth rates of the 
liver show that a much faster kinetic growth rate is seen in the future liver 
remnant of patients with ALPPS compared with portal vein ligation or portal 
vein embolization. Data from the Mayo clinic show that the kinetic growth rate of 
the FLR in ALPPS is the same as healthy liver after a liver resection or the same 
as regeneration after living donor liver donation or transplantation8.  Thus there 
is a limited effect of ALPPS in terms of liver regeneration compared with other 
types of liver resection. It is probably important to acknowledge this when 
considering patient safety and the timing of second stage procedures. What has 
become very clear is that a failure to exhibit effective regeneration in the future 
liver remnant is predictive of poor outcome from ALPPS9. 
 
Many of my personal concerns around ALPPS were to do with the way it was 
introduced and the resulting poor case selection leading to high mortality and 
morbidity [for many patients]. It is pleasing to see that more contemporary 
reports are clarifying selection criteria both in embarking on the procedure and, 
in particular, in defining who should proceed to the second stage. It is also 
gratifying that contemporary reports of ALPPS show improvements of morbidity 
and mortality for patients. It is reasonable to ask therefore where ALPPS should 
fit into the surgical armamentarium today.  There are certain patients in whom 
there is a risk of tumour escape if a two stage procedure is performed or 
preoperative portal vein embolization strategies are used. Perhaps greater 
thought should be given to key questions concerning individual patients and 
their suitability for ALPPS and I have suggested some of these in Figure 1. There 
may be a role for ALPPS in these situations if there is no clear alternative surgical 
strategy. For the moment the conclusion of the recently released meta-analysis 
of outcomes following ALPPS concludes “ALPPS is associated with greater future 
liver remnant hypertrophy and a higher rate of completion of stage 2, but this may 
be at the price of greater morbidity and mortality.”10 
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One of the key future developments for liver surgery has to be to standardize 
measurement of the volume function relationship which will permit a more safe 
approach to liver surgery in whatever form this is undertaken. 
 
 
Acknowledgement: Thanks to Professor O James Garden for critical reading of 
this manuscript 
 
Legend Figure 1 
 
 
Suggested pathway for decision making for patient selection and progression of 
ALPPS or procedures requiring portal vein embolization or ligation.  
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Figure 1 
 
Suggested pathway for decision making for patient selection and progression of 
ALPPS or procedures requiring portal vein embolization or ligation.  
 
 
 
 
 
 
* Patients with hilar cholangiocarcinoma should not undergo ALPPS but should 
be managed using approaches using PVE/PVL if FLR is considered inadequate. 
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